The biotech is developing drugs that target the biology of aging to treat obesity, cardiovascular disease, and more ...
17m
Zymeworks’ Ziihera Sets New Survival Benchmark in First-Line HER2-Positive Gastric Cancer Trial
Zymeworks reported positive Phase 3 results from the HERIZON-GEA-01 trial of its engineered HER2-targeted antibody Ziihera (zanidatamab-hrii) in combination with chemotherapy, with or without PD-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback